Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

BACKGROUND: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemias (Ph-positive ALL) with clinically approved inhibitors of the Bcr/Abl tyrosine kinase frequently results in the emergence of a leukemic clone carrying the T315I mutation in Bcr/Abl, which confers resistance to the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Fei, Fei, Lim, Min, Schmidhuber, Sabine, Moll, Jürgen, Groffen, John, Heisterkamp, Nora
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2012
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3489684/
https://ncbi.nlm.nih.gov/pubmed/22721004
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-11-42
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki